Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Wednesday

Atea Pharmaceuticals (NASDAQ:AVIR) is projected to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.

Atea Pharmaceuticals Stock Performance

Shares of AVIR opened at $3.14 on Tuesday. The firm has a market capitalization of $265.20 million, a price-to-earnings ratio of -1.52 and a beta of 0.19. Atea Pharmaceuticals has a one year low of $2.75 and a one year high of $4.60. The stock’s fifty day moving average is $3.19 and its 200-day moving average is $3.38.

Insider Activity

In other news, Director Franklin M. Berger sold 359,606 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the transaction, the director now directly owns 451,897 shares of the company’s stock, valued at approximately $1,287,906.45. This trade represents a 44.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 17.80% of the company’s stock.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.